Raffaele Baffa, M.D., Ph.D., joined Ziopharm as Chief Medical Officer in November 2020. Most recently, he was Head of R&D and Chief Medical Officer for Medisix, an immune engineering company developing novel cellular therapies to address T cell malignancies. Previously, Dr. Baffa was Vice President and Therapeutic Area Head of Oncology, Global Clinical Development for Shire, and, subsequent to the acquisition of the oncology division by Servier, he served as Chief Medical Officer of Servier Pharmaceuticals. Raffaele has also held industry leadership positions as Executive Director, Early Oncology Development and Clinical Research at Pfizer and at Sanofi, where he was Head of Translational Sciences – External Science & Innovation, Global Biotherapeutics. Dr. Baffa earned an M.D. from University of Padova, School of Medicine, and a Ph.D. from University of Parma, both in Italy. As an associate professor at the Kimmel Cancer Center, Thomas Jefferson University in Philadelphia, he also served as Director of Urology Research and as Co-Director of the Genito-Urinary Cancer Program. Dr. Baffa has authored more than 100 peer-reviewed articles, invited articles and book chapters.